Tags: Drug.
Itolizumab (INN trade name Alzumab) is a ‘first in class’ humanized IgG1 monoclonal antibody developed by Biocon. It selectively targets CD6 a pan T cell marker involved in co-stimulation adhesion and maturation of T cells. Itolizumab by binding to CD6 down regulates T cell activation causes reduction in synthesis of pro-inflammatory cytokines and possibly plays an important role by reducing T cell infiltration at sites of inflammation.